Abstract 766P
Background
Prolongation of overall treatment time (OTT) in carcinoma cervix is well known to adversely affect local control and survival. The OTT would be unduly prolonged if brachytherapy (BT) was started only after completion of external beam radiation (EBRT) as multiple insertions are required for high-dose-rate BT. This study was carried out to compare treatment outcomes of shortening the OTT by interdigitated BT as opposed to conventional sequential BT in terms of late toxicities, disease free survival (DFS) and overall survival (OS).
Methods
The study included 70 patients of cancer cervix who met the inclusion criteria. Patients were randomized into study and control arms. All the patients received EBRT (45Gy/20 fractions over 4 weeks) with concurrent Cisplatin and 3 fractions of BT (7 Gy/fraction). Patients in the control arm received weekly BT after one week following EBRT to complete the entire treatment in 7 weeks. In the study arm, BT was interdigitated with EBRT after 15 fractions. Subsequent BT fractions were given on days 27 and 34 to complete the treatment in 5 weeks. The two groups were compared in terms of late toxicities, DFS and OS at a follow up of two years.
Results
A total of 63 patients completed the planned treatment. The OTT and mean biologically equivalent dose (BED10Gy) after reduction for accelerated repopulation was significantly better in the study arm (p=0.001). At two years of follow up, 80% of patients in the study arm and 72.72% in the control arm had no local or distant failure. Also, death occurred in 13.33% patients and 18.18% patients in the study and control arm, respectively. No statistically significant difference was reached in terms of OS and DFS despite a trend towards better DFS in the interdigitated BT arm. The incidence of late lower gastro-intestinal toxicities was found to be higher in the study arm but this difference was not significant.
Conclusions
Interdigitated BT with chemoradiation appears to be an acceptable option for shortening OTT with similar survival outcomes and acceptable toxicities in comparison to sequential brachytherapy. Owing to a shorter OTT, this approach is radiobiologically superior with a more efficient utilization of machines at centers with heavy patient load.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
780P - Role of BRCA1 promotor methylation in homologous recombination deficiency (HRD) in high-grade ovarian cancer
Presenter: Heidelinde Fiegl
Session: Poster session 11
781P - Chemotherapy sensitivity score based on ex vivo 3D tumour testing to predict clinical response for ovarian cancer patients
Presenter: Janneke Walraven
Session: Poster session 11
782P - Correlation between chemotherapy response score (CRS) and germline BRCA1/2 (gBRCA) status in women diagnosed with FIGO stage IIIC/IV high-grade serous ovarian cancer (HGSOC)
Presenter: Daniel Netto
Session: Poster session 11
783P - The role of JARID1B in ovarian cancer
Presenter: Katharina Leitner
Session: Poster session 11
784P - HPV integration promotes HPV carcinogenesis via remodeling chromatin interactions between universal stripe factors and super-enhancer in HPV-related carcinoma
Presenter: Canhui Cao
Session: Poster session 11
785P - The predictive role of circulating exosomal PD-L1 in cervical cancer immunotherapy
Presenter: Wenjie Tang
Session: Poster session 11
786P - Antitumor activity of farletuzumab ecteribulin in a panel of endometrial cancer patient-derived xenografts with four different molecular subtypes
Presenter: Kosei Hasegawa
Session: Poster session 11
787P - A NGS panel for molecular classification of endometrial carcinoma
Presenter: Hao Wen
Session: Poster session 11
788P - Molecular profiling of p53 mutant endometrial cancer reveals distinct subgroups with opportunities for personalized therapeutic approaches
Presenter: Felix Blanc-Durand
Session: Poster session 11
789P - Real-world (RW) duration of treatment in first-line maintenance (1Lm) niraparib monotherapy in epithelial ovarian cancer (EOC): CHAR1ZMA study
Presenter: Floor Backes
Session: Poster session 11